Will the results include any new partnership, licensing, or collaboration announcements?

Answer

Based on the information you’ve provided, there is no indication that the upcoming second‑quarter 2025 results for BioLineRx (BLRX) will contain any new partnership, licensing, or collaboration announcements.

Why this conclusion is drawn:

What this means for your question

• No mention of a new partnership, licensing, or collaboration is present in the headline, the brief summary, or the metadata you shared.
• Because the news is categorized under Earnings and the only content described is the upcoming conference call, the primary purpose appears to be a financial update rather than a strategic partnership announcement.

Caveats & next steps

• Limited excerpt: The snippet you have is short. Companies sometimes include “operating highlights” (including new deals) later in the full press release or during the conference call itself. If you need absolute certainty, you should:
  1. Read the full press release (usually available on BioLineRx’s investor relations site or the PRNewswire archive).
     
  2. Listen to or review the transcript of the August 14, 2025 conference call—companies often disclose new collaborations during the call even if they aren’t in the pre‑release text.
• Future updates: If a partnership or licensing deal is announced after the press release (e.g., during the call), it would be captured in the call’s transcript or in a subsequent news article.

Bottom line: With the current information at hand, we cannot confirm that the second‑quarter 2025 results will include any new partnership, licensing, or collaboration announcements. To be certain, you would need to consult the complete press release or the call transcript when they become available.